home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

PureTech Health plc - American Depositary Shares (NQ:PRTC)

17.42 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, May 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about PureTech Health plc - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

PureTech Founded Entity Akili Interactive Announces Filing of Registration Statement on S-4 in Connection with its Proposed Business Combination with Social Capital Suvretta Holdings Corp. I

February 15, 2022

From PureTech Health

Via Business Wire

PureTech to Present at the SVB Leerink 11th Annual Global Healthcare Conference

February 10, 2022

From PureTech Health

Via Business Wire

PureTech Founded Entity Gelesis to Launch Plenity® National Media Campaign That Challenges Restrictive Dieting Norms

January 31, 2022

From PureTech Health plc

Via Business Wire

PureTech Founded Entity Akili Interactive, a Leader in Digital Medicine, to Become Publicly Traded Through Combination with Social Capital Suvretta Holdings Corp. I

January 26, 2022

From PureTech Health plc

Via Business Wire

12 Health Care Stocks Moving In Friday's Intraday Session ↗

January 21, 2022

Gainers Biophytis (NASDAQ:BPTS) shares rose 12.3% to $5.28 during Friday's regular session. The market value of their outstanding shares is at $68.0 million. Intra-...

Via Benzinga

Gelesis, Maker Of Weight Loss Pill, Concludes SPAC Deal; Trading Kickstarts Today ↗

January 14, 2022

PureTech Health plc (NASDAQ: PRTC) founded entity Gelesis Inc, maker of weight management aid, has completed its business combination with Capstar Special...

Via Benzinga

PureTech Founded Entity Gelesis, the Maker of Plenity® for Weight Management, Will Debut as a Publicly Traded Company Following the Closing of its Business Combination with Capstar

January 14, 2022

From PureTech Health plc

Via Business Wire

PureTech to Present at 40th Annual J.P. Morgan Healthcare Conference

January 07, 2022

From PureTech Health plc

Via Business Wire

PureTech’s LYT-100 (Deupirfenidone) Achieves 50% Reduction in Healthy Older Adults Experiencing GI-Related Adverse Events Compared to Pirfenidone

January 06, 2022

From PureTech Health plc

Via Business Wire

PureTech Founded Entity Gelesis Appoints Inogen Co-Founder and Former CFO Ali Bauerlein to Board of Directors and Audit Committee

January 05, 2022

From PureTech Health plc

Via Business Wire

PureTech Provides End of Year Report on Key Progress Across Wholly Owned Programs and Founded Entities

December 16, 2021

From PureTech Health

Via Business Wire

PureTech Presents Preclinical Proof-of-Concept Data for LYT-300 (Oral Allopregnanolone) as Potential Treatment for Neurological and Neuropsychological Conditions

December 08, 2021

From PureTech Health plc

Via Business Wire

PureTech Advances Wholly-Owned Candidate LYT-300 (Oral Allopregnanolone) into Clinical Study for Potential Treatment of Neurological and Neuropsychological Conditions

December 07, 2021

From PureTech Health plc

Via Business Wire

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

December 02, 2021

Gainers Biofrontera (NASDAQ:BFRI) shares ...

Via Benzinga

PureTech Founded Entity Gelesis Announces FDA-Cleared Weight Management Approach, Plenity®, Now Broadly Available and Leading Nutrition Authority Joy Bauer, MS, RDN, CDN, Joins as Chief Nutrition Officer

December 01, 2021

From PureTech Health plc

Via Business Wire

PureTech Founded Entity Gelesis Receives $30 Million Plenity® Order from Ro

November 18, 2021

From PureTech Health plc

Via Business Wire

PureTech Announces Publication of Phase 1 Results for LYT-100 in the Journal Clinical Pharmacology in Drug Development and Provides Timing Updates

November 16, 2021

From PureTech Health plc

Via Business Wire

PureTech Announces Participation in Two Upcoming Investor Conferences

November 15, 2021

From PureTech Health plc

Via Business Wire

PureTech Presents Clinical Trial Design Supporting Wholly Owned Immuno-Oncology Candidate LYT-200 at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

November 12, 2021

From PureTech Health plc

Via Business Wire

PureTech Receives Orphan Drug Designation for Wholly Owned Candidate LYT-200 for the Treatment of Pancreatic Cancer

November 11, 2021

From PureTech Health plc

Via Business Wire

PureTech Founded Entity Karuna Therapeutics and Zai Lab Announce Strategic Collaboration for Development, Manufacturing, and Commercialization of KarXT in Greater China

November 09, 2021

From PureTech Health plc

Via Business Wire

PureTech Announces Participation at the Jefferies London Healthcare Conference

November 09, 2021

From PureTech Health plc

Via Business Wire

PureTech Is Pleased to Note Publication in Nature’s Scientific Reports Featuring the Gelesis Foundational Biomimetic Platform for Treating Obesity and Conditions Related to Diet-Induced Gut Damage

November 01, 2021

From PureTech Health plc

Via Business Wire

PureTech Founded Entity Vedanta Biosciences Appoints Simona Levi as Chief Legal Officer and Corporate Secretary

October 14, 2021

From PureTech Health plc

Via Business Wire

PureTech Founded Entity Vedanta Announces Positive Topline Phase 2 Data for VE303 in High-Risk C. difficile Infection and Exercise of $23.8 Million Option by BARDA

October 05, 2021

From PureTech Health plc

Via Business Wire

PureTech Founded Entity Sonde Health Launches Vocal Biomarker Technology to Monitor Mental Health and Well-Being

October 05, 2021

From PureTech Health plc

Via Business Wire

PureTech Founded Entity Akili Announces Topline Results from Shionogi Phase 2 Study in Japan

September 29, 2021

From PureTech Health plc

Via Business Wire

PureTech Announces Publication of New Preclinical Research from Collaborators that Supports Mesenteric Lymphatic Dysfunction as a Potential Cause of and Therapeutic Target for Obesity and Insulin Resistance

September 20, 2021

From PureTech Health plc

Via Business Wire

PureTech to Present at Oppenheimer Fall Healthcare Life Sciences and MedTech Summit

September 14, 2021

From PureTech Health plc

Via Business Wire

PureTech Founded Entity Vor Biopharma Announces VOR33 Granted U.S. FDA Fast Track Designation for Acute Myeloid Leukemia

September 10, 2021

From PureTech Health plc

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com